Premium
De novo autoimmune hepatitis after liver transplantation: A focus on glutathione S‐transferase theta 1
Author(s) -
IbáñezSamaniego Luis,
Salcedo Magdalena,
Vaquero Javier,
Bañares Rafael
Publication year - 2017
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.24652
Subject(s) - medicine , autoimmune hepatitis , liver transplantation , pathogenesis , transplantation , liver disease , glutathione s transferase , immunology , hepatitis , disease , pathophysiology , gastroenterology , glutathione , enzyme , biology , biochemistry
De novo autoimmune hepatitis (DAIH) is a rare clinical condition with features that resemble those of autoimmune hepatitis (AIH) in patients undergoing liver transplantation (LT) for nonautoimmune liver disease. The diagnosis of this entity has been based on the presence of biochemical and histological patterns similar to those observed in the primary AIH, although several considerations must be taken into account. The impact of DAIH on graft survival is relevant, and early diagnosis and treatment is associated with a good longterm outcome. Although glutathione S‐transferase theta 1 (GSTT1) alloimmune recognition has been shown to be involved in the pathogenesis of DAIH, further studies are necessary to fully determine its pathogenic mechanisms and risk factors. We review the pathophysiology, the most common histological patterns, the treatment strategies, and the longterm outcomes of DAIH after LT with a special focus on GSTT1. Liver Transplantation 23:75–85 2017 AASLD .